Ribo soumet une demande d'essai clinique européen pour une étude de phase I pour l'ARNsi RBD3133 ciblant l'INHBE

Phase 1RBD3133Positive

AI Analysis

Summary

Ribo submitted a Phase I clinical trial application (CTA) to European authorities for RBD3133, a siRNA targeting INHBE. The study marks the advancement of the company's RNA interference platform into clinical development.

Clinical Trial Data

Phase

Phase I

Importance:5/10

Sentiment:

0.50

Phase 1Clinical Trial ApplicationsiRNAEuropeINHBE

Related Companies

$06938.HK

Read the original article

Published by PR Newswire Biotech on October 8, 2026 11:04 PM

Read Original